Adalimumab relieves hidradenitis suppurativa

December 18, 2012
Adalimumab relieves hidradenitis suppurativa
For patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment with once-weekly adalimumab is associated with improvements in pain and inflammation, according to a study published online Dec. 17 in the Annals of Internal Medicine.

(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment with once-weekly adalimumab is associated with improvements in pain and inflammation, according to a study published online Dec. 17 in the Annals of Internal Medicine.

Alexa B. Kimball, M.D., M.P.H., of Harvard Medical School in Boston, and colleagues conducted a parallel, randomized trial involving 154 adult patients with moderate-to-severe HS who did not respond to or who were intolerant of . Patients were allocated to receive placebo or 40 mg adalimumab every week or every other week (EOW) for 16 weeks. All patients were switched to EOW at the start of an open-label 36 week phase, while those who had a suboptimal response could switch to weekly dosing at that point.

After 16 weeks of treatment, the researchers found that a clinical response was achieved in 9.6 percent of those who received EOW adalimumab, 17.6 percent of those who received weekly adalimumab, and 3.9 percent of placebo-treated patients. Serious adverse events were reported in 5.8 percent of EOW, 7.8 percent of weekly, and 3.9 percent of placebo-treated patients. Compared with the placebo group, patients who received weekly adalimumab reported significantly higher improvements in outcomes and pain. Patients who switched from weekly to EOW adalimumab treatment showed a reduction in clinical response.

"This phase 2 dose-ranging study showed evidence of efficacy and tolerability of adalimumab in HS," the authors write. "Inflammation and pain were reduced, and impairment of health-related quality of life and increased."

The study was funded by , the manufacturer of ; several authors disclosed financial ties to Abbott.

Explore further: UVB preferred for treatment of moderate to severe psoriasis

More information: Full Text (subscription or payment may be required)

Related Stories

UVB preferred for treatment of moderate to severe psoriasis

February 24, 2012

(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the ...

Study compares effectiveness of psoriasis treatments

April 20, 2012

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

Reasons for discontinuation vary by psoriasis treatment

August 10, 2012

(HealthDay) -- The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.

Immunogenicity strongly impacts response to adalimumab in RA

December 13, 2012

(HealthDay)—For patients with rheumatoid arthritis (RA), long-term clinical outcomes are good with etanercept and adalimumab; but for adalimumab, treatment response is strongly dependent on the presence or absence of anti-adalimumab ...

Recommended for you

Anti-inflammatory mechanism of dieting and fasting revealed

February 16, 2015

Researchers at Yale School of Medicine have found that a compound produced by the body when dieting or fasting can block a part of the immune system involved in several inflammatory disorders such as type 2 diabetes, atherosclerosis, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.